Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial

Contemp Clin Trials. 2020 Jun:93:105999. doi: 10.1016/j.cct.2020.105999. Epub 2020 Apr 14.

Abstract

Introduction: Focal therapy (FT) targets individual areas of cancer within the prostate, providing oncological control with minimal side-effects. Early evidence demonstrates encouraging short-medium-term outcomes. With no randomized controlled trials (RCT) comparing FT to radical therapies, Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (CHRONOS) will compare the cancer control of these two strategies.

Patients and methods: CHRONOS is a parallel phase II RCT for patients with clinically significant non-metastatic prostate cancer, dependent upon clinician/patient decision, patients will enrol into either CHRONOS-A or CHRONOS-B. CHRONOS-A will randomize patients to either radical treatment or FT. CHRONOS-B is a multi-arm, multistage RCT comparing focal therapy alone to FT with neoadjuvant agents that might improve the current focal therapy outcomes. An internal pilot will determine the feasibility of, and compliance to, randomization. The proposed definitive study plans to recruit and randomize 1190 patients into CHRONOS-A and 1260 patients into CHRONOS-B.

Results: Primary outcome in CHRONOS-A is progression-free survival (transition to salvage local or systemic therapy, development of metastases or prostate-cancer-related mortality) and in CHRONOS-B is failure-free survival (includes the above definition and recurrence of clinically significant prostate cancer after initial FT). Secondary outcomes include adverse events, health economics and functional outcomes measured using validated questionnaires. CHRONOS is powered to assess non-inferiority of FT compared to radical therapy in CHRONOS-A, and superiority of neoadjuvant agents with FT in CHRONOS-B.

Conclusion: CHRONOS will assess the oncological outcomes after FT compared to radical therapy and whether neoadjuvant treatments improve cancer control following one FT session.

Trial registration: ClinicalTrials.gov NCT04049747.

Keywords: Cryotherapy; Focal therapy; High-intensity focused ultrasound; Multi-centre; Prospective study; Prostate cancer.

Publication types

  • Clinical Trial Protocol
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ablation Techniques* / adverse effects
  • Ablation Techniques* / education
  • Ablation Techniques* / methods
  • Androgen Antagonists / therapeutic use
  • Anilides / therapeutic use
  • Brachytherapy / adverse effects
  • Brachytherapy / economics
  • Brachytherapy / methods
  • Clinical Trials, Phase II as Topic
  • Costs and Cost Analysis
  • Equivalence Trials as Topic
  • Finasteride / therapeutic use
  • Humans
  • Male
  • Multicenter Studies as Topic
  • Neoadjuvant Therapy / methods
  • Neoplasm Recurrence, Local
  • Nitriles / therapeutic use
  • Progression-Free Survival
  • Prospective Studies
  • Prostatectomy* / adverse effects
  • Prostatectomy* / economics
  • Prostatectomy* / methods
  • Prostatic Neoplasms* / mortality
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / therapy
  • Radiotherapy / adverse effects
  • Radiotherapy / economics
  • Radiotherapy / methods
  • Randomized Controlled Trials as Topic
  • Research Design
  • Tosyl Compounds / therapeutic use
  • United Kingdom

Substances

  • Androgen Antagonists
  • Anilides
  • bicalutamide
  • Finasteride
  • Nitriles
  • Tosyl Compounds

Associated data

  • ClinicalTrials.gov/NCT04049747